Comment in

• Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.

  Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP. Klag T, et al. J Hepatol. 2017 Apr;66(4):862-863. doi: 10.1016/j.jhep.2017.01.002. Epub 2017 Jan 9. J Hepatol. 2017. PMID: 28082147 No abstract available.
• Reply to: "Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C".

  EASL Recommendations for Treatment of Hepatitis C 2016 Panel. Electronic address: easloffice@easloffice.eu. EASL Recommendations for Treatment of Hepatitis C 2016 Panel. Electronic address: easloffice@easloffice.eu. J Hepatol. 2017 May;66(5):1103. doi: 10.1016/j.jhep.2017.01.021. Epub 2017 Feb 3. J Hepatol. 2017. PMID: 28167321 No abstract available.
• Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.

  Grebely J, Swan T, Hickman M, Bruneau J, Bruggmann P, Dalgard O, Litwin A, Backmund M, Dore GJ; International Network for Hepatitis in Substance Users. Grebely J, et al. J Hepatol. 2017 May;66(5):1101-1103. doi: 10.1016/j.jhep.2016.12.028. Epub 2017 Feb 3. J Hepatol. 2017. PMID: 28167323 Free PMC article. No abstract available.
• Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?

  Hupa KL, Deterding K, Port K, Kimmann M, Manns MP, Wedemeyer H, Cornberg M. Hupa KL, et al. J Hepatol. 2018 Apr;68(4):851-853. doi: 10.1016/j.jhep.2017.10.035. Epub 2017 Nov 22. J Hepatol. 2018. PMID: 29175536 No abstract available.